It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones,” said Ugur Sahin, CEO and Co-founder of BioNTech.Ībout the Phase 3 Data from Adolescents 12-15 Years of Age The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant. This is especially true for our children. “Across the globe, we are longing for a normal life. “We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.” “We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. These are topline results from a pivotal Phase 3 trial in 2,260 adolescents. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. NEW YORK & MAINZ, Germany-(BUSINESS WIRE)- Pfizer Inc.
The companies also provided an update on the Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years.Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of the Emergency Use Authorization (EUA) and EU Conditional Marketing Authorization for BNT162b2 The companies plan to submit these data to the U.S.In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated.Research and Business Development Partnerships.You may select options to allow automatic updates.Unleashing the next wave of scientific innovations.Enter your personal name, the Organization "Lehigh University", and the license information located in the license document on the Software Page When the installation is finished, launch Stata.Choose the location for the Stata program and the default location where files will be saved.Select the "Installation Type" from the "Licensed Software" field in the license document on the Software Page.Click Continue/Next and agree to the license agreement Follow the installation window prompts.
In Mac, open the dmg file and double click the Install Stata icon. In Windows, run the exe file and grant permission to "make changes to this device". Choose the correct option for your OS (Mac/Windows/Linux)
The following information is a supplement to the full guide, and provides information about the Lehigh-specific license(s). Go to Sata's Installation Guide for a full step-by-step guide to download and install the software, and activate the license.
Stata uses multiple pieces of info as the license including a serial number, code, and authorization. Go to Lehigh's Software Page to find the installer and license information. Download the software to your own computer In most cases, the software available via LUapps is the newest version available. LUapps is a virtual software delivery system that allows users to access a variety of software titles. You can use Stata virtually through LUapps or install it locally on your own computer. Lehigh provides access to multiple versions of Stata.